SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing heightened activity driven by a reported domestic chip manufacturing partnership with Apple, a catalyst that has revitalized the stock's turnaround narrative. Community discussion is polarized between optimistic investors betting on long-term structural re-rating and skeptics who view the price action as an overextended pump fueled by political headlines rather than new information.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is seeing significant retail and institutional interest as investors anticipate a major 52-week clinical data readout for sonelokimab in hidradenitis suppurativa. Community discussion is heavily focused on the potential for a transformative valuation re-rating, with many actively debating the probability of an M&A catalyst following recent clinical progress and best-in-class performance expectations.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp is seeing intense volatility and record-breaking momentum driven by a severe, multi-year supply crunch in NAND flash and enterprise SSDs, fueling a massive re-rating of the sector as institutions bet on sustained AI-driven demand. While the stock's parabolic ascent has sparked a fierce tug-of-war between retail bulls celebrating generational wealth and skeptical bears calling for an imminent correction due to extreme technical overextension.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

The iShares Semiconductor ETF is experiencing intense volatility and community division, fueled by aggressive retail speculation, institutional gamma squeezes, and heated debates over the sustainability of the current AI-driven valuation cycle. Investors are actively trading between leveraged bull and bear positions, with many reacting to geopolitical headlines and potential macro shifts while debating whether current levels represent a permanent structural shift or a classic speculative blow-off top.

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure Corp. is generating significant buzz as investors anticipate upcoming data center lease announcements, with recent federal grid rulings further validating the company's shift toward power-intensive AI infrastructure. The stock's performance on the TSX exchange while US markets were closed has fueled community speculation regarding institutional pre-positioning ahead of Russell 3000 inclusion and potential hyperscaler partnerships.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending due to heightened community speculation surrounding the pending 80th event milestone for the REGAL Phase 3 trial and anticipation of a potential buyout. Investors are actively debating the impact of elevated short interest, high borrow rates, and the company's progress toward late-stage commercialization.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is trending as investors react to a breakthrough AI-powered imaging partnership with Midjourney, which is fueling massive daily volume and intense short-squeeze speculation. While bulls are highlighting the potential for significant long-term growth driven by new semiconductor chip licensing, skeptics are expressing concerns over high volatility, potential dilution, and the company's path to consistent profitability.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors aggressively accumulate shares ahead of expected data center lease announcements in Kentucky, driven by the sector's pivot toward high-performance AI infrastructure. The community remains focused on the company's multi-gigawatt build-out potential and the high institutional interest in its capacity to secure prime, long-term power contracts.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

Semiconductor stocks are experiencing intense volatility as investors weigh the rapid growth of AI-driven infrastructure demand against uncertainties surrounding upcoming Federal Reserve policy shifts. Community sentiment is deeply divided, with bulls viewing periodic pullbacks as tactical buying opportunities for leveraged exposure, while bears highlight potential overvaluation and concerns regarding institutional rotation.

JetBlue Airways Corp. engages in the provision of air transportation services. Its brands include jetBlue, jetBlue Vacations, Paisly, and TrueBlue. It operates through the following geographic segments: Domestic and Canada, Caribbean and Latin America, and Atlantic. The company was founded by David Gary Neeleman in August 1998 and is headquartered in Long Island City, NY.

Jetblue Airways Corp

JetBlue is currently trending as investors speculate on potential M&A activity, with community discourse fueled by reports that the company has hired advisors to explore strategic alternatives, including a possible acquisition. While some market participants are bullish on the stock as a potential buyout target, others remain cautious, citing significant debt levels and the broader headwinds facing the airline sector from elevated fuel costs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio

Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio...

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1

ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from its pivotal ALPHA3 study.

Allogene Therapeutics Q1 2026 Earnings Call Transcript

Allogene Therapeutics (ALLO) Projected to Post Quarterly Earnings on Tuesday

Allogene Therapeutics (NASDAQ:ALLO) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-allogene-therapeutics-inc-stock...

Annie Yoshiyama Sells 9,586 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Annie Yoshiyama sold 9,586 shares of the business's stock in a transaction on Tuesday, April 21st. The shares were sold at an average...

Allogene Therapeutics (NASDAQ:ALLO) SVP Annie Yoshiyama Sells 9,586 Shares

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Annie Yoshiyama sold 9,586 shares of the company's stock in a transaction dated Tuesday, April 21st. The stock was sold at an average...

Allogene Therapeutics (NASDAQ:ALLO)  Shares Down 6%   - Should You Sell?

Allogene Therapeutics (NASDAQ:ALLO) Trading Down 6% - What's Next...

HC Wainwright Issues Optimistic Estimate for ALLO Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Analysts at HC Wainwright boosted their Q2 2026 EPS estimates for Allogene Therapeutics in a report released on Thursday, April 16th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.15) per share for th...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has received an average rating of "Moderate Buy" from the fifteen research firms that are presently covering the company, Marketbeat...

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Allogene Therapeutics Inc

ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.00
Prev Close	$1.96
Open	$2.02
Dividend Yield	0.00%
50-Day Moving Average	$2.17
Beta	1.69
Avg. Volume	6.63M
PE Ratio	-2.60

52-Week High	$4.46
52-Week Low	$0.9842
Market Capitalization	$690.31M
EPS (Annual)	-$0.8652
Price to Book	1.76
Revenue Per Employee	$0.00

ALLOAllogene Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALLO News